Theriva Biologics (NYSEAMERICAN:TOVX) Shares Down 1.4% – Time to Sell?

Shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) fell 1.4% on Monday . The company traded as low as $1.10 and last traded at $1.20. 19,166 shares were traded during trading, a decline of 98% from the average session volume of 1,002,475 shares. The stock had previously closed at $1.22.

Theriva Biologics Trading Down 2.4 %

The company’s 50 day simple moving average is $1.41. The stock has a market capitalization of $3.34 million, a price-to-earnings ratio of -0.04 and a beta of 1.22.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP purchased a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned 6.13% of Theriva Biologics at the end of the most recent reporting period. 6.17% of the stock is currently owned by institutional investors.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.